Epilepsy is a complex brain disease, in which individuals are pre-disposed to show spontaneous seizures. Idiopathic epilepsy (IE) is classified as epilepsy of predominantly genetic or presumed genetic origin and in which there are no gross abnormalities of the structure of the brain nor other relevant underlying diseases causing seizure activity. IE is the most common chronic neurological condition in domestic dogs, estimated to affect 0.6% of dogs, but markedly higher in some breeds e.g. 17-33% in the Belgian Shepherd. Quality-of-life is also limited by side-effects of the currently used anti-epileptic drugs (AEDs), and quantity-of-life is potentially reduced due to an increased risk of premature death secondary to epilepsy. Further challenges faced by veterinarians treating dogs with epilepsy, and owners of affected dogs ARE (i) drug-resistance: a lack of response to currently available AEDs affecting up to 60-86% of treated dogs, and (ii) neurobehavioural changes comorbid with IE, which are poorly understood in dogs but highly prevalent in people with epilepsy. Our own studies have previously found that as few as 14% of dogs become seizure free on treatment, and increases in fear/anxiety and defensive aggression are seen following the onset of IE. These common features make the dog an ideal translational model for spontaneously occurring drug resistant epilepsy. It is clear that there is a need to gain a deeper understanding of IE in the dog to identify risk factors for (i) the development of IE, (ii) the lack of response to available AED therapies, (iii) the development of behavioural changes, and (iv) the interplay between these factors, so that future efforts to treat or prevent IE are targeted and effective. Genetic markers of both epilepsy and AED response have had limited success thus far, may be hard to interpret and account for only a limited proportion of susceptibility. In this study we instead investigate biochemical by-products of metabolic pathways (the 'metabolome') and the microorganisms living in association with the body (the 'microbiome') which reflects the interaction between an organism's genome and its environment and are a better potential indicator of observed characteristics, which can be potentially modified as treatment strategy. Although metabolomic markers of IE have not yet been found, profiles of anxiety have been identified in humans and mice. The microbiome has not yet been studied in IE development, but is involved in the metabolism of AEDs, and changes have been associated with anxiety levels through brain-gut interactions. This research programme will characterise types of disease presentation, the variation in behavioural characteristics, variation in metabolites in the metabolome, and differences in micro-organism populations in the microbiome in dogs with and without IE to identify novel biological markers of both the disease, drug response and behavioural signs (and associations between these factors) that could provide new perspectives on the underlying disease biology and provide new treatment targets. We will study these novel measures in two stages: firstly, a case-control study of breed and age-matched dogs with and without IE recruited from our hospital populations to directly compare profiles; secondly, a prospective cohort study of 5000 puppies from the South of England to identify physical and behavioural profiles measured before seizure onset that act as risk factors for IE development. Urine and faecal samples will be collected for metabolomic and microbiomic analysis. Behavioural testing will characterise aspects of the dogs' underlying affective state, to reveal whether IE and drug-resistance are associated with an underlying characteristic that predisposes individuals to perform anxiety-related behaviours. This novel and comprehensive approach is needed to unravel the mechanisms underlying IE, the occurrence of drug-resistance and behavioural abnormalities.

Doctoral Training Partnerships: a range of postgraduate training is funded by the Research Councils. For information on current funding routes, see the common terminology at https://www.ukri.org/apply-for-funding/how-we-fund-studentships/. Training grants may be to one organisation or to a consortia of research organisations. This portal will show the lead organisation only.

Nematodes (roundworms) are members of the Phylum Nematoda. There are >25,000 species of nematodes and they are outnumbered only by the Arthropods. Their success is due to their ability to occupy a diverse range of habitats. They can either be free-living or parasites of humans, animals and plants. Nematode parasites are a common source of human disease where 1 in 4 people carry at least one nematode species. Human parasitic diseases are mainly restricted to the developing world where poverty, inadequate health care provision, and poor living conditions favour their survival. Some of the most prevalent human nematode parasites live in the gasterointestinal (GI) system feeding on human tissue, blood and gut contents. For example, Ascaris lumbricoides is one of the largest GI nematodes and can cause serious health problems associated with intestinal blockage and impaired growth, especially in children. In livestock, nematode parasites can be a significant problem as they impact not only on the health and well-being of the animal but also on the productivity and subsequent profitability of the farming industry. Haemonchus contortus and Teladorsagia circumcincta are the most pathogenic nematodes of sheep and goats. They are blood-feeders and heavy infections can lead to severe anaemia and animal death. Nematodes are also problematic to the crop industry. They can infect food crops such as tomatoes and potatoes or utility grasses including football pitches or golf courses. Meloidogyne spp are a particular problem because they infect a wide range of plant hosts. They impair plant health by setting up feeding sites in the plant root, removing nutrients needed for plant growth. Unfortunately the drugs that are available to treat parasitic nematode infections no longer work effectively or are environmentally toxic. We cannot continue to treat nematode infections with the current range of drugs and we must now actively seek new drug targets and develop novel drugs. This is particularly important to the UK as we have to ensure the sustainability of livestock farming for future food production. This project aims to uncover novel drug targets for the treatment of nematode parasites of livestock. In this project we will collaborate with an animal-health pharmaceutical company to accelerate the chance of identifying a novel drug target at which new drugs could be directed. This approach will make use of scientific research skills and the expertise of the pharmaceutical industry in drug discovery. In order to find new drug targets for nematode parasites, we must first identify proteins that are important to nematode biology and survival. Recently there has been an increase in the availability of gene sequences for a number of important parasitic nematodes, like those described above. We will search through these sequences and find those which code for protein targets which may be essential to parasite survival. We will select sequences that are found in multiple parasites so that we can identify a drug target which could be used to treat multiple nematode diseases. We will then use a technique called RNA interference (RNAi) which allows us to switch off genes in the parasitic nematode to find out their function. For example, if we switch off a gene and the nematode dies or stops moving/feeding/reproducing then we have identified a good drug target candidate as the nematode can no longer infect or remain in its host. We will perform RNAi in a model nematode parasite (Ascaris suum) that we can easily collect from pig intestines at local abattoirs and maintain in the lab. Once we have switched off the target genes, we will determine the impact to the parasite by examining how they survive, behave, move, reproduce, and respond to stimulants. We will then select the five 'best' targets, based on their impact to nematode biology, and deliver these to the pharmaceutical industry who will develop drugs against them.

Recent research in our laboratories has identified 2 new bocaviruses in swine. We have isolated these 2 viruses, which are each antigenically different, from farms in Northern Ireland with clinical postweaning multisystemic wasting syndrome (PMWS) and preliminary partial molecular characterisation of these viruses has shown that they share genetic homology with bovine parvovirus-1 (BPV-1), canine minute virus (CMV) and human bocavirus (HBoV). To date, the disease-causing significance of these novel swine bocaviruses, as primary pathogens or perhaps as immunosuppresive triggers for other infectious agents, is undetermined. Investigation of the importance of these viruses in swine and humans as potential emerging pathogens is urgently required. It is possible that these newly identified swine bocaviruses could be pathogenic to swine and may also have a zoonotic potential. Whether swine bocaviruses have implications as a debilitating primary infection in pigs and/or humans or as a contributory infection, perhaps acting as an immunosuppressive infectious agent, merits urgent investigation. This genomic sequence data of the viruses generated to date will be expanded and used to produce tools for detection of swine bocaviruses in tissue samples and blood. Monoclonal and polyclonal antibodies will be produced to all 2 new swine bocaviruses to further study the biological characterisation, epidemiology and potential pathogenesis of swine bocaviruses in swine and other species. Experimental infections of swine will be carried out to determine sites of replication of these viruses and potential pathogenesis. Archived tissue samples from diseased and non-diseaed swine (including foetal material) in the UK will be examined and prospective field studies will be carried out. The possible 'contamination' of swine biologicals, including vaccines with swine bocavirus will also be investigated. On the basis of recent findings reported for other bocaviruses (including human bocavirus) we believe that our newly discovered swine bocaviruses may have the capacity to cause respiratory infections and/or reproductive problems and/or contribute to the severity of PMWS in swine. We also hypothesise that other existing porcine viral pathogens may have an increased severity due to the presence of these new viruses. Therefore, the hypothesis to be tested is that 'newly discovered swine bocaviruses will cause respiratory and other disease scenarios in pigs and that the virus isolates will exacerbate symptoms in pigs already suffering from other disorders. Additionally an experimental model of infection with swine bocavirus could prove useful in the study of human bocavirus infections. In this project hitherto-unavailable reagents, diagnostic tests and experimental models will be developed and applied to provide information relating to the characterisation, detection, epidemiology and pathogenicity of newly discovered bocaviruses of swine. Those newly discovered isolates will be fully characterised at nucleotide level and biologically using current techniques that have already been applied in our laboratory for the discovery of other novel viral pathogens.